[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 386,067
  • Shares Outstanding, K 60,135
  • Annual Sales, $ 216,110 K
  • Annual Income, $ -220,470 K
  • EBIT $ -153 M
  • EBITDA $ -143 M
  • 60-Month Beta 0.65
  • Price/Sales 1.74
  • Price/Cash Flow N/A
  • Price/Book 1.34

Options Overview Details

View History
  • Implied Volatility 81.04% (-6.79%)
  • Historical Volatility 59.71%
  • IV Percentile 47%
  • IV Rank 17.49%
  • IV High 332.52% on 11/14/25
  • IV Low 27.75% on 09/04/25
  • Expected Move (DTE 2) 0.43 (6.61%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 348
  • Volume Avg (30-Day) 550
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 17,975
  • Open Int (30-Day) 16,470
  • Expected Range 6.01 to 6.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.50
  • Number of Estimates 2
  • High Estimate $-0.49
  • Low Estimate $-0.52
  • Prior Year $-0.46
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.15 +4.55%
on 05/12/26
7.74 -16.87%
on 05/06/26
-0.73 (-10.20%)
since 04/13/26
3-Month
5.73 +12.22%
on 02/20/26
9.94 -35.31%
on 03/10/26
+0.34 (+5.58%)
since 02/13/26
52-Week
3.81 +68.80%
on 05/15/25
9.94 -35.31%
on 03/10/26
+2.45 (+61.56%)
since 05/13/25

Most Recent Stories

More News
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

WASHINGTON , May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in May...

VNDA : 6.43 (+0.16%)
Vanda: Q1 Earnings Snapshot

Vanda: Q1 Earnings Snapshot

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

WASHINGTON , May 6, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2026.

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals: Can Prescription Momentum Justify the Valuation Before Bysanti's Regulatory Verdict?

Barchart Research What to Expect from VNDA Earnings VNDA Generated May 5, 2026 Current Price $7.39 EPS Estimate $$-0.53 Consensus Rating Moderate Buy Average Move 7.71% Vanda Pharmaceuticals: Can Prescription...

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUSâ„¢ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

WASHINGTON , May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUSâ„¢ (tradipitant) is now commercially available across the United States for...

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUSâ„¢ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

WASHINGTON , May 1, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUSâ„¢ (tradipitant) is now commercially available across the United States for...

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Conference Call and Webcast to Follow

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

WASHINGTON , April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...

ANAB : 62.69 (-4.41%)
VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

WASHINGTON , April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22,...

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

WASHINGTON , April 9, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification....

VNDA : 6.43 (+0.16%)

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 6.67
2nd Resistance Point 6.60
1st Resistance Point 6.51
Last Price 6.43
1st Support Level 6.35
2nd Support Level 6.28
3rd Support Level 6.19

See More

52-Week High 9.94
Fibonacci 61.8% 7.60
Fibonacci 50% 6.87
Last Price 6.43
Fibonacci 38.2% 6.15
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.